⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMMX News
Immix Biopharma, Inc. Common Stock
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
globenewswire.com
IMMX
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX